- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01117844
Proton Radiation For Meningiomas and Hemangiopericytomas
Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
The primary objectives of this study are feasibility and safety. The study will be deemed infeasible if greater than 10% of pts experience one of the following:
Patient cannot be given treatment because anatomy is such that a dosimetrically satisfactory treatment plan cannot be devised.
(95% of target volume covered by 95% of the dose)
- Patient is unable to tolerate 20% of treatments (for any reason unable to set patient up within acceptable limits of tolerance, patient unable to tolerate treatment position or immobilization for duration of treatment) using proton radiotherapy (up to 80% of treatments could be delivered using photons).
- Patient is unable to complete all of his/her treatments within 7 days of estimated date of treatment completion or requires a treatment break greater than 5 days. Toxicity will be deemed unacceptable if greater than 20% of patients experience acute toxicity, as defined in Section 7.12.
Secondary Objectives:
- To assess acute side effects from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.
- To assess quality of life outcomes, with a focus on the rate of severe fatigue at 6 and 12 months from end of treatment.
- To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.
- To compare the dose distribution to tumor and surrounding normal structures using DVHs (Dose Volume Histograms) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.
- To determine 1-yr local control and progression-free and overall survival using proton radiotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center of the Unviersity of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically confirmed diagnosis of WHO I-III meningiomas and hemangiopericytomas:
WHO grade I :
- Tumor that are newly diagnosed and tumors that are incompletely excised
- Tumors that have recurred post resection
WHO grade II:
- Any tumor, either completely or incompletely excised
- Any recurrent tumor
WHO grade III and hemangiopericytoma:
- Any tumor, either completely or incompletely excised
- Any recurrent tumor
- Patients must have a Karnofsky Performance Status of 60. Age greater than 18 years Patients must be able to provide informed consent.
- Adequate bone marrow function: WBC greater than 4000/mm3, platelets greater than 100,000 mm3.
- Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc.). Hysterectomy or menopause must be clinically documented.
Exclusion Criteria:
- Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma).
- Pregnant women, women planning to become pregnant and women that are nursing. Actively being treated on any other therapeutic research study.
- Prior radiation to the brain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Proton radiation
|
Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and Safety
Time Frame: 90 days
|
For proton to deemed feasible, no greater than 10% of patients should experience a) Patient cannot be given treatment because anatomy is such that a dosimetically satisfactory treatment plan cannot be devised, b) Patient is unable to tolerate 20% of treatments using proton therapy, and c) patient is unable to complete all treatments within 7 days of estimated date of treatment completion
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late Toxicity
Time Frame: 90 days
|
Late toxicity is defined as any grade 3 or higher toxicity, excluding seizures, observed later than 90 days from start of radiation therapy.
|
90 days
|
Fatigue - Brief Fatigue Inventory (BFI)
Time Frame: 5 Years
|
Fatigue will be scored by the Brief Fatigue Inventory (BFI), a validated instrument, which will be evaluated at the following time points: Pre-radiation, weekly during treatment, at 3, 6, 9, 12 months post-radiation and then every 6 months.
It is expected that BFI score will increase (as fatigue worsens) in the first 6-9 months post-radiation and then the BFI score will decrease (as fatigue improves) at 12-24 months post-radiation.
Proton radiotherapy is expected to improve fatigue as compared to photon radiotherapy.
|
5 Years
|
Health Related Quality of Life
Time Frame: 5 Years
|
Health Related Quality of Life will be followed using the following: EQ-5D European Quality of Life Index, Fact-G Functional Assessment of Cancer Therapy-General (FACT-G), and Fact-BR Functional Assessment of Cancer Therapy-Brain.
Fact-BR will be evaluated at the same time points as the BFI.
EQ-5D and Fact-G will be evaluated at pre-radiation, at 3, 6, 9, 12 months postradiation and then every 6 months.
|
5 Years
|
Cumulative total dose (Gy) to normal brain tissue
Time Frame: 8 Weeks
|
Cumulative total dose (Gy) to normal brain tissue will be estimated based on dosimetry plans for both proton and photon.
Proton radiotherapy is expected to decrease exposure to normal brain tissues.
|
8 Weeks
|
Progression free survival (PFS) and overall survival (OS)
Time Frame: 5 Years
|
PFS and OS are defined as the time from start of radiotherapy to first documented progression (event for PFS), death due to any cause or last patient contact alive.
|
5 Years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms, Connective Tissue
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Neoplasms, Fibrous Tissue
- Meningioma
- Hemangiopericytoma
- Solitary Fibrous Tumors
Other Study ID Numbers
- UPCC 24309
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningioma
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
Northwestern UniversityNational Cancer Institute (NCI); NovoCure Ltd.RecruitingAtypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
Nancy Ann Oberheim Bush, MDMerck Sharp & Dohme LLCRecruitingRecurrent Meningioma | Grade I Meningioma, Adult | Grade II Meningioma, Adult | Grade III Meningioma, AdultUnited States
-
National Cancer Institute (NCI)RecruitingGrade 2 Meningioma | Grade 3 Meningioma | Recurrent MeningiomaUnited States
-
University of NebraskaChimerixNot yet recruitingMeningioma | Refractory Meningioma | Relapsed MeningiomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingIntracranial Meningioma | Grade II MeningiomaCanada, United States, Japan, Saudi Arabia, India
-
Ohio State UniversityRecruitingCognitive Impairment | Cognitive Decline | Meningioma | Skull Base Meningioma | Frontal Meningioma | Temporal Meningioma | Post-Surgical CognitionUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingMeningioma | Anaplastic Meningioma | Meningioma AtypicalItaly
-
National Cancer Institute (NCI)CompletedRecurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Meningioma | Adult Grade III MeningiomaUnited States
Clinical Trials on Proton Radiation
-
Loma Linda UniversityCompletedProstate CancerUnited States
-
P-CureHadassah Medical OrganizationRecruitingBrain Cancer | Thoracic Cancer | Head Cancer | Neck Cancer | Pancreatic Cancer Non-resectableIsrael
-
University of FloridaCompleted
-
Proton Collaborative GroupActive, not recruitingProstate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8United States
-
Massachusetts General HospitalRecruiting
-
Massachusetts General HospitalNational Cancer Institute (NCI)UnknownInvasive Breast CancerUnited States
-
Ass. Prof. Jan NymanRecruitingThymus Neoplasms | Cardiotoxicity | Pulmonary ToxicitySweden
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingResectable Lung Non-Small Cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Unresectable Head and Neck Squamous Cell Carcinoma | Unresectable Oropharyngeal... and other conditionsUnited States